Clinical Trials Logo

Filter by:
NCT ID: NCT01622062 Completed - Rabies Clinical Trials

Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen

Start date: June 29, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the 4-site "one-week" post-exposure prophylaxis (PEP) regimen as a possible alternative to the 2-site updated Thai Red Cross (TRC) PEP regimen. Primary objective: - To demonstrate that PEP using the new "one-week, 4-site" (4-4-4-0-0) intradermal (ID) vaccination regimen is non-inferior to PEP using the updated TRC (2-2-2-0-2) ID vaccination regimen. Secondary objectives: - Primary immunization: To describe the immune response in each group at Day 0, Day 14 and Day 90. - Antibody persistence: To describe rabies virus-neutralizing antibody persistence during the 5 years after completion of PEP in each group. - Booster vaccination: To describe the immune response induced by a single-visit 4-site intradermal booster vaccination in each group at Year 5. - Safety: To describe the safety profile of each group after the primary and booster vaccinations.

NCT ID: NCT01615198 Completed - Clinical trials for Essential Hypertension

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

Start date: August 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to access the efficacy and safety of LCZ696 compared to olmesartan in elderly Asian patients for the treatment of hypertension.

NCT ID: NCT01613326 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

GLOW5
Start date: June 2012
Phase: Phase 3
Study type: Interventional

This study compared the efficacy and safety of NVA237 with tiotropium in patients with moderate to severe COPD. Tiotropium belongs to the same drug class as NVA237.

NCT ID: NCT01609582 Terminated - Type 2 Diabetes Clinical Trials

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Start date: June 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate no excess risk of cardiovascular (CV) composite events exists following long term treatment with TAK-875 compared with placebo.

NCT ID: NCT01603641 Completed - Cerebral Palsy Clinical Trials

BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity

Start date: November 5, 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric lower limb spasticity.

NCT ID: NCT01603628 Completed - Cerebral Palsy Clinical Trials

BOTOX® Treatment in Pediatric Lower Limb Spasticity

Start date: September 11, 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with lower limb spasticity.

NCT ID: NCT01603615 Completed - Stroke Clinical Trials

BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity

Start date: October 30, 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity.

NCT ID: NCT01603602 Completed - Stroke Clinical Trials

BOTOX® Treatment in Pediatric Upper Limb Spasticity

Start date: July 12, 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with upper limb spasticity.

NCT ID: NCT01601613 Completed - Clinical trials for Acquired Bleeding Disorder

Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever

Start date: July 2001
Phase: Phase 2
Study type: Interventional

This trial is conducted in Asia. The aim of this is to investigate the efficacy and safety of activated recombinant human factor VII (rFVIIa) in achieving haemostasis in patients with Dengue haemorrhagic fever (DHF).

NCT ID: NCT01600963 Withdrawn - Clinical trials for Multi-drug Resistant Tuberculosis

A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis

Start date: March 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide safety and efficacy data for TMC207 and to demonstrate that TMC207 added to a background regimen (BR) is superior to treatment with the BR plus placebo.